Skip to main content
. 2020 Nov 13;8(2):e001367. doi: 10.1136/jitc-2020-001367

Figure 6.

Figure 6

Survival of pancreatic ductular adenocarcinoma (PDAC) liver metastasis model mice that underwent treatment. (A) Experimental schedule showing treatment timing: the PDAC liver metastasis mice received treatment 10 times, twice a week from day 7 to day 39, and survival percentage was monitored until day 72. (B) Survival curves of PDAC liver metastasis mice that received: no treatment (only phosphate-buffered saline; n=7), anti-programmed cell death 1 (anti-PD-1) Ab (n=12), gemcitabine (GEM) (n=7), GEM plus anti-PD-1 Ab (n=6), or GEM plus anti-PD-1 Ab plus anti-CD8 Ab (n=7). The log-rank test was performed to obtain the p values: no treatment/anti-PD-1 Ab=0.492723; no treatment/GEM=0.000172; no treatment/GEM plus anti-PD-1 Ab=0.000446; anti-PD-1 Ab/GEM=0.000034; anti-PD-1 Ab/GEM plus anti-PD-1 Ab=0.000098; GEM/GEM plus anti-PD-1 Ab=0.034672; and GEM plus anti-PD-1 Ab/GEM plus anti-PD-1 Ab plus anti-CD8 Ab=0.0345.